Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Pain in Anti-MAG Neuropathy
    ABSTRACT & COMMENTARY

    Pain in Anti-MAG Neuropathy

    February 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Anti-MAG Antibodies: Clinical and Therapeutic Aspects

    Anti-MAG or Not?

    Related Products

    Neuropathy in Myeloma

    Small Fiber Neuropathy in Critical Illness

    Keywords

    Neuropathy

    pain

    anti-mag

    By Russell L. Chin, MD

    Associate Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Chin reports no financial relationships relevant to this field of study.

    SYNOPSIS: Most patients with anti-MAG neuropathy complain of painful paresthesias or dysesthesias, but unlike diabetic neuropathy, these symptoms are not severe and do not affect quality of life as much as motor weakness.

    SOURCE: Rajabally YA, Delmont E, Hiew FL, et al. Prevalence, correlates and impact of pain and cramps in anti-MAG neuropathy: A multicenter European study. Eur J Neurol 2018;25:135-141.

    Anti-MAG neuropathy is associated with an IgM monoclonal gammopathy and manifests typically as a slowly progressive, symmetric, predominantly sensory neuropathy affecting distal lower more than upper extremities. Sensory loss, involving all modalities, typically occurs earlier than weakness, which eventually develops in most patients in the distal extremities. Unlike chronic inflammatory demyelinating polyneuropathy, proximal strength typically is spared. Hand tremor may develop later in the disease course. Demyelinating features are noted by electromyography/nerve conduction studies in more than 90% of patients, particularly severely prolonged distal motor latencies and severe conduction velocity slowing, while conduction block is uncommon. Widening of myelin lamellae can be noted on ultrastructural examination of the nerve. No significant benefit from plasmapheresis, steroids, intravenous immunoglobulin, chlorambucil, or other immunosuppressive agents has been found. Rituximab has been reported to be beneficial1; however, clinical trials have been negative. Longer duration studies with adequate outcome measures may be necessary.2

    In this study, pain of any type was reported in 80% of clinically stable patients with anti-MAG neuropathy. Paresthesiae/dysesthesiae were the most common pain subtypes. Cramps involving the lower extremities were reported in 64% (35/55) of patients, with concomitant upper extremity involvement in 29% (10/35). Correlation analyses showed multiple positive associations between pain severity and cramp severity, location, and frequency with various measures of quality of life and disability.

    COMMENTARY

    Pain typically is associated more with diabetic and amyloid neuropathies because of small fiber sensory involvement. It also is reported with demyelinating neuropathy, such as Guillain-Barré syndrome, presumably because of direct inflammation of nerve roots. Rajabally et al highlighted the fact that pain also may be a prominent but under-recognized feature of inflammatory, immune-mediated neuropathies such as anti-MAG neuropathy, in particular.3

    In this study, dysesthesias/paresthesias were present in more than 70% of patients. Although these symptoms generally are not considered painful by physicians or patients, they were associated independently with some measures of fatigue and a poorer quality of life. As would be expected, other types of pain (such as burning, pressing, or paroxysmal pain) also correlated positively with other quality-of-life metrics.

    Cramps were described in the lower extremities more frequently, but hand involvement (specifically the severity and frequency of cramps) was most relevant to disability and quality of life. A beneficial role for physiotherapy was suggested by the finding of inverse correlations between: 1) cramp severity and level of physiotherapy, and 2) cramps interfering with sleep and level of physiotherapy.

    This article raises awareness of the high frequency of pain and cramps that might affect quality of life in anti-MAG neuropathy. Non-drug treatments, such as physiotherapy for cramps, may be helpful and should not be neglected. Any treatment interventions will need to affect quality of life measures positively to be meaningful for the patient.

    REFERENCES

    1. Svahn J, Petiot P, Antoine JC, et al. Anti-MAG antibodies in 202 patients: Clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 2017; Oct. 25. doi: 10.1136/jnnp-2017-316715. [Epub ahead of print].
    2. Pruppers MH, Merkies IS, Notermans NC. Recent advances in outcome measures in IgM-anti-MAG+ neuropathies. Curr Opin Neurol 2015;28:486-493.
    3. Pazzaglia C, Briani C, Nobile-Orazio E, et al. Occurrence and characterization of pain in immune-mediated neuropathies: A multicenter prospective study. Eur J Neurol 2011;18:177-183.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 6) - February 2018
    February 1, 2018

    Table Of Contents

    Neuroimmunology and Movement Disorders: When Should We Test for Autoantibodies?

    Targeting Hypersensitive Corticostriatal Terminals to Treat Restless Legs Syndrome

    Functional Imaging Studies in Parkinson’s Disease

    Myasthenia Gravis, MuSK, and Pregnancy

    Pain in Anti-MAG Neuropathy

    Serum Tau as a Reliable Biomarker of Outcome After Cardiac Arrest

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing